| Autor: |
Reinemeyer CR; East Tennessee Clinical Research, Knoxville, Tennessee, USA. creinemey@aol.com., Charles SD; Bayer HealthCare LLC, Animal Health Division, Kansas, USA., Buch J; Bayer HealthCare LLC, Animal Health Division, Kansas, USA., Settje T; Bayer HealthCare LLC, Animal Health Division, Kansas, USA., Altreuther G; Bayer HealthCare AG, Animal Health Division, R&D Parasiticides, 51368, Leverkusen, Germany., Cruthers L; Professional Laboratory Research Services, North Carolina, USA., McCall JW; TRS Laboratories, Georgia, USA., Young DR; Young Veterinary Research Services, Turlock, Callfornia, USA., Epe C; Institute of Parasitology, Hannover School of Veterinary Medicine, Hannover, Germany. |
| Abstrakt: |
Eleven controlled studies were conducted in the United States and Europe to evaluate the efficacy of a topical solution of emodepside (3 mg/kg)+praziquantel (12 mg/kg) (Profender, Bayer AG, Leverkusen, Germany) against infection with various stages of the ascarid nematodes Toxocara cati and Toxascaris leonina. Infections were induced by administration of larvated ascarid eggs, and stage-specific efficacy was evaluated by treating cats at scheduled intervals post-inoculation. All studies featured random allocation to treatment groups, placebo-treated control animals and assessment of outcome measures by masked personnel. The product (emodepside+praziquantel topical solution) was 100% effective against mature adults and immature adult T. cati. In addition, it was 96.8% effective against third stage larvae and at least 99.4% effective against fourth stage larvae of T. cati, respectively. Efficacy against mature, immature adult and L4 stages of T. leonina exceeded 93.4%, but regulatory "adequacy of infection" criteria were not met in some studies. No adverse reactions to treatment were noted in cats treated with the emodepside+praziquantel topical solution. |
Full text from SpringerLink